p-Cresyl Sulfate Drives Valvular Calcification via Klotho/SIRT1 Disruption

Study Background and Research Question

Calcific aortic valve disease (CAVD) is a prevalent and severe complication among patients with chronic kidney disease (CKD), yet the molecular drivers connecting CKD and CAVD remain incompletely defined. One focus of recent research is the role of protein-bound uremic toxins, particularly p-cresyl sulfate (PCS, also termed p-tolyl hydrogen sulfate), which accumulates in the blood as renal clearance declines. While elevated PCS is recognized as a biomarker for uremia-related cardiovascular risk, its direct mechanistic contribution to valvular calcification had not been fully elucidated. The current study, published by Li et al. (DOI:10.3892/mmr.2026.13872), addresses this gap by investigating whether PCS drives calcification in aortic valvular interstitial cells (VICs) and clarifies the involvement of klotho and SIRT1 signaling pathways.

Key Innovation from the Reference Study

The central innovation of this research lies in establishing a direct, mechanistically defined link between PCS exposure and VIC calcification, mediated by disruption of the klotho/SIRT1 axis. The study goes beyond correlative observations by dissecting the signaling events—specifically, the activation of hypoxia-inducible factor-1α (HIF-1α), increased nuclear factor kappa B (NF-κB) acetylation, and upregulation of runt-related transcription factor 2 (RUNX2)—that underlie PCS-induced calcific transformation. Furthermore, the research demonstrates how exogenous klotho supplementation and SIRT1 activation can mitigate these pathological changes, positioning the klotho/SIRT1 pathway as a promising target for vascular complication studies in CKD.

Methods and Experimental Design Insights

Li et al. employed both in vitro and in vivo models to comprehensively assess the impact of PCS on valvular calcification:

• In vitro VIC model: Porcine aortic VICs were exposed to PCS at concentrations of 10 or 100 μM for 7 days. Treatments included co-incubation with recombinant klotho (100 pM), the HIF-1α inhibitor PX-478 (0.5 μM), and the SIRT1 activator SRT1720 (1 mM).
• Assessment techniques: Calcification was quantified using Alizarin Red S staining; klotho, SIRT1, RUNX2, NF-κB acetylation, and HIF-1α levels were evaluated via western blotting and immunohistochemistry.
• In vivo PCS-CKD model: Rats were induced to model CKD, then treated with PCS, and aortic valves were analyzed for RUNX2 expression and klotho levels.

This multifaceted approach allowed the authors to interrogate both molecular signaling and phenotypic endpoints relevant to CAVD pathogenesis.

Protocol Parameters

• PCS treatment (in vitro): 10–100 μM PCS for 7 days to induce VIC calcification.
• Klotho supplementation: 100 pM recombinant klotho co-incubated with PCS-treated VICs to test rescue effects.
• SIRT1 activation: 1 mM SRT1720 applied during PCS treatment to probe pathway modulation.
• HIF-1α inhibition: 0.5 μM PX-478 included in select conditions to dissect hypoxic signaling contributions.
• In vivo PCS dose: Dosing in CKD rat models as per experimental workflow, with aortic valve tissue collected for immunohistochemical analysis.

Core Findings and Why They Matter

The study presents several convergent lines of evidence:

• PCS exposure significantly increased calcium deposition in VICs, upregulated RUNX2 and HIF-1α, and enhanced NF-κB acetylation, while reducing klotho expression.
• Supplementation with klotho or activation of SIRT1 (with SRT1720) attenuated PCS-induced VIC calcification and normalized molecular markers, including downregulation of RUNX2.
• In vivo, klotho supplementation mitigated RUNX2 upregulation in aortic valves of PCS-treated CKD rats.

These findings clarify the molecular bridge between PCS accumulation and the development of calcific aortic valve pathology in CKD, underscoring the value of endothelial dysfunction research using PCS as a model toxin. The results also highlight the klotho/SIRT1 pathway as a key node for therapeutic intervention in CAVD and related vascular diseases.

Comparison with Existing Internal Articles

The mechanistic insights from Li et al. (reference study) are consistent with prior analyses such as "p-Cresyl Sulfate Drives Aortic Valve Calcification via Klotho/SIRT1 Axis" and "p-Cresyl Sulfate Promotes Valve Calcification via Klotho/SIRT1 Pathways", both of which emphasize PCS's direct pro-calcific effects on valvular cells through suppression of klotho and SIRT1 signaling. Furthermore, the workflow recommendations in "p-Cresyl Sulfate in Vascular Calcification & Endothelial Models" and "p-Cresyl Sulfate in Endothelial Dysfunction & Calcification Models" provide researchers with detailed protocols for leveraging PCS in experimental systems to probe cardiovascular and renal disease mechanisms. This cross-validation of findings strengthens the reproducibility and translational relevance of PCS-based models for uremic toxin clearance research and biomarker discovery.

Limitations and Transferability

Despite its strengths, the study is subject to several limitations. First, the use of porcine VICs and rodent CKD models may not fully recapitulate human pathophysiology, and interspecies differences in klotho/SIRT1 signaling could affect translatability. The PCS concentrations used for in vitro experiments, while pathophysiologically relevant, may not precisely mirror the dynamic exposure profiles seen in CKD patients. Additionally, the study focuses on a specific signaling axis; other pathways contributing to endothelial dysfunction and calcification in CKD may remain unaddressed. Finally, while klotho and SIRT1 modulation showed therapeutic promise in preclinical models, clinical translation will require further validation and safety assessment.

Research Support Resources

For researchers aiming to replicate or extend these findings, high-purity p-Cresyl sulfate (SKU A8895) is available for advanced cardiovascular and renal disease modeling. Detailed handling and solubility information can be found in the product dossier, ensuring reliable preparation for p-cresyl sulfate endothelial cell proliferation assays and wound healing inhibition studies. Used in conjunction with the protocols outlined above, this reagent supports precise investigation of klotho/SIRT1-mediated pathways in CAVD and related vascular pathologies.